XNYS
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.84 | -0.64 | +23.81% | $0 | ✅ Beat | +0.89% | +0.98% | — |
| 2026-03-05 | Q4 2025 | -0.75 | -1.43 | -90.67% | $0 | ❌ Miss | +1.43% | -8.41% | -5.46% |
| 2025-12-11 |
| Q3 2025 |
| — |
| -8.07 |
| — |
| $10,000 |
| — |
| — |
| — |
| — |
Showing last 3 quarters.